333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985
Van Herpen, C.M, Banerji, U, Mommers, E.C, Koper, N.P, Goedings, P, Lopez, J, Awada, A, Fiebrich, H.B, Aftimos, P.G
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article